This story originally ran on Sept. 15.

Cell Biosciences last week announced it had entered into a definitive agreement to acquire Alpha Innotech for $20 million in a deal that further accelerates Cell Biosciences' transition to a full commercial operation.

Under the terms of the deal, anticipated to close in 60 days, Cell Biosciences would pay $1.50 for each share of Alpha Innotech stock for a total of $17.9 million in cash. It also would assume $2.1 million of outstanding debt from Alpha Innotech.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.

Oct
10
Sponsored by
PerkinElmer

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.